Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 158

Sort by

Sort Order Select

Journal Articles

First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis

Blood (2024) 143 (14): 1399–1413.

https://doi.org/10.1182/blood.2023021349

Published: 2024

Includes: Supplemental data

Journal Articles

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Blood (2023) 142 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2023-188305

Published: 2023

Journal Articles

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Blood (2023) 142 (Supplement 1): 2871.

https://doi.org/10.1182/blood-2023-179537

Published: 2023

Journal Articles

Oral Anticoagulant Therapy in Patients with Philadelphia-Negative Myeloproliferative Neoplasms: A Real-Life Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants

Fabrizio Cavalca, Ivan Civettini, Stefano Bonfanti, Carlo Gambacorti-Passerini, Elena Maria Elli

Blood (2023) 142 (Supplement 1): 1838.

https://doi.org/10.1182/blood-2023-187139

Published: 2023

Journal Articles

Evaluating the Performance of Large Language Models in Hematopoietic Stem Cell Transplantation Decision Making

Ivan Civettini, Arianna Zappaterra, Daniele Ramazzotti, Bianca Maria Granelli, Giovanni Rindone, Andrea Aroldi, Stefano Bonfanti, Federica Colombo, Marilena Fedele, Giovanni Grillo, Matteo Parma, Paola Perfetti, Elisabetta Terruzzi, Carlo Gambacorti-Passerini, Fabrizio Cavalca

Blood (2023) 142 (Supplement 1): 3726.

https://doi.org/10.1182/blood-2023-185854

Published: 2023

Journal Articles

Preliminary Results of Phase 2 Open Label Study of Lorlatinib Monotherapy in Relapsed/Refractory ALK + Lymphomas Previously Treated with Other Tyrosine Kinase Inhibitors

Alessia Ripamonti, Andrea Aroldi, Federica Cocito, Luca Guerra, Lavinia Monaco, Bianca Maria Granelli, Lara Mussolin, Carlo Gambacorti-Passerini

Blood (2023) 142 (Supplement 1): 4474.

https://doi.org/10.1182/blood-2023-186702

Published: 2023

Journal Articles

Targeting CD24 “Don't Eat Me” Signal Restores Phagocytic Activity of Nurse-like Cells from Patients with Chronic Lymphocytic Leukemia

Andrea Aroldi, Mario Mauri, Daniele Ramazzotti, Simone Piane, Matteo Villa, Federica Malighetti, Chiara Borella, Elisa Bossi, Federica Cocito, Carolina Steidl, Luca Mologni, Rocco Piazza, Carlo Gambacorti-Passerini

Blood (2023) 142 (Supplement 1): 4197.

https://doi.org/10.1182/blood-2023-190359

Published: 2023

Journal Articles

First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis

Blood (2023) 142 (Supplement 1): 4135.

https://doi.org/10.1182/blood-2023-189094

Published: 2023

Journal Articles

Hemoglobin Monza: A New Variant of Unstable Hemoglobin

Ivan Civettini, Paola Corti, Arianna Zappaterra, Amedeo Messina, Andrea Aroldi, Andrea Biondi, Fabrizio Cavalca, Francesca Crosti, Giulia Maria Ferrari, Luca Mologni, Alberto Piperno, Daniele Ramazzotti, Alfonso Zambon, Fabio Rossi, Chiara Scollo, Carlo Gambacorti-Passerini

Blood (2023) 142 (Supplement 1): 5273.

https://doi.org/10.1182/blood-2023-184846

Published: 2023

Journal Articles

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Blood (2023) 142 (Supplement 1): 6544.

https://doi.org/10.1182/blood-2023-188454

Published: 2023

Journal Articles

Effects of CD24 "Don't Eat Me" Signal Blockade in Combination with Anti-CD47 and Rituximab in Mantle-Cell Lymphoma

Andrea Aroldi, Mario Mauri, Matteo Villa, Federica Malighetti, Federica Cocito, Claudia Voena, Roberto Chiarle, Luca Mologni, Rocco Piazza, Carlo Gambacorti-Passerini

Blood (2022) 140 (Supplement 1): 3136–3138.

https://doi.org/10.1182/blood-2022-159247

Published: 2022

Journal Articles

Neutrophil to Lymphocyte Ratio (NLR) at Diagnosis Is a Predictor of Venous Thrombosis and Poor Outcome in Patients with Prefibrotic Primary Myelofibrosis

Fabrizio Cavalca, Francesca Palandri, Novella Pugliese, Alessia Ripamonti, Ambra Di Veroli, Mattia Biondo, Carlo Gambacorti-Passerini, Roberto Latagliata, Elena Maria Elli

Blood (2022) 140 (Supplement 1): 9711–9712.

https://doi.org/10.1182/blood-2022-165456

Published: 2022

Journal Articles

Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

Michael Mauro, Ronald Paquette, Rüdiger Hehlmann, Loretta A. Williams, Stuart L. Goldberg, Mauricette Michallet, Carlo Gambacorti-Passerini, Derek Tang, Irene S. DeGutis, Ali McBride, Lori Parsons, Monica Z. Montelongo, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 9624–9625.

https://doi.org/10.1182/blood-2022-163080

Published: 2022

Journal Articles

Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study

Jorge E. Cortes, Stuart L. Goldberg, Ronald Paquette, Loretta A. Williams, Rüdiger Hehlmann, Mauricette Michallet, Carlo Gambacorti-Passerini, Derek Tang, Irene S. DeGutis, Ali McBride, Lori Parsons, Monica Z. Montelongo, Michael Mauro

Blood (2022) 140 (Supplement 1): 3902–3903.

https://doi.org/10.1182/blood-2022-163063

Published: 2022

Journal Articles

Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study

Blood (2022) 140 (Supplement 1): 1504–1506.

https://doi.org/10.1182/blood-2022-162207

Published: 2022

Journal Articles

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Blood (2022) 140 (Supplement 1): 205–207.

https://doi.org/10.1182/blood-2022-166452

Published: 2022

Journal Articles

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Blood (2022) 140 (17): 1845–1857.

https://doi.org/10.1182/blood.2021014586

Published: 2022

Includes: Supplemental data

Journal Articles

Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK + anaplastic large cell lymphoma

Blood (2022) 139 (5): 717–731.

https://doi.org/10.1182/blood.2020008136

Published: 2022

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial

Carlo Gambacorti-Passerini, Tim H Brümmendorf, Elisabetta Abruzzese, Kevin R. Kelly, Vivian G. Oehler, Valentín Garcia-Gutiérrez, Henrik Hjorth-Hansen, Thomas Ernst, Eric Leip, Simon Purcell, Gerald Luscan, Andrea Viqueira, Frank Giles, Andreas Hochhaus

Blood (2021) 138 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2021-150352

Published: 2021

Journal Articles

Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results

Sarit Assouline, Maria Cristina Miggiano, Elisabetta Abruzzese, Chiara Elena, Giovanni Caocci, Susanne Saussele, Francesca Lunghi, Alberto Alvarez-Larran, Barbara Mora, Sigi Petrela, Laura Antolini, Carlo Gambacorti-Passerini, Alessandra Iurlo

Blood (2021) 138 (Supplement 1): 1476.

https://doi.org/10.1182/blood-2021-150496

Published: 2021

NARROW

First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study

Oral Anticoagulant Therapy in Patients with Philadelphia-Negative Myeloproliferative Neoplasms: A Real-Life Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants

Evaluating the Performance of Large Language Models in Hematopoietic Stem Cell Transplantation Decision Making

Preliminary Results of Phase 2 Open Label Study of Lorlatinib Monotherapy in Relapsed/Refractory ALK + Lymphomas Previously Treated with Other Tyrosine Kinase Inhibitors

Targeting CD24 “Don't Eat Me” Signal Restores Phagocytic Activity of Nurse-like Cells from Patients with Chronic Lymphocytic Leukemia

First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis

Hemoglobin Monza: A New Variant of Unstable Hemoglobin

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Effects of CD24 "Don't Eat Me" Signal Blockade in Combination with Anti-CD47 and Rituximab in Mantle-Cell Lymphoma

Neutrophil to Lymphocyte Ratio (NLR) at Diagnosis Is a Predictor of Venous Thrombosis and Poor Outcome in Patients with Prefibrotic Primary Myelofibrosis

Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study

Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK + anaplastic large cell lymphoma

Efficacy and Safety of Bosutinib in Previously Treated Patients with Chronic Myeloid Leukemia: Final Results from the Byond Trial

Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only